MediGene AG (ETR:MDG1) received a €12.00 ($13.95) target price from equities research analysts at Independent Research GmbH in a research note issued to investors on Tuesday. The firm presently has a “neutral” rating on the stock. Independent Research GmbH’s price objective indicates a potential upside of 9.14% from the company’s previous close.
Other equities research analysts have also issued research reports about the stock. Baader Bank set a €19.00 ($22.09) target price on shares of MediGene AG and gave the company a “buy” rating in a research note on Thursday, November 9th. Oddo Securities set a €12.00 ($13.95) target price on shares of MediGene AG and gave the company a “buy” rating in a research note on Tuesday, August 8th.
MediGene AG (ETR:MDG1) opened at €11.00 ($12.78) on Tuesday. MediGene AG has a 1-year low of €8.38 ($9.74) and a 1-year high of €15.24 ($17.72).
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/11/14/independent-research-gmbh-analysts-give-medigene-ag-mdg1-a-12-00-price-target.html.
About MediGene AG
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.